此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Neonatal Gastro-Esophageal Reflux Disease (GERD) Management Trial (GMT)

2020年7月24日 更新者:Sudarshan Jadcherla

Pathophysiology of the Aerodigestive Reflex in Infants: GERD Management Trial

The overall purpose of the investigator's study is to evaluate the causes of and treatment for feeding difficulty in infants with Gastro-esophageal Reflux Disease (GERD). New treatments can be possible only if the cause is known. Many infants have GERD and feeding difficulties, such as sucking and swallowing problems, vomiting, or delayed emptying of the stomach. Some of these infants have difficulty in protecting their airway during feeding or during reflux, and as a result can breathe fluid into their lungs or hold their breath. Most GERD treatments are done based on experience, but there is no scientific proof that these methods work for infants. GERD and feeding difficulties can lead to longer hospitalization and more stress for the family.

In this clinical trial, the investigators are developing new methods to help with diagnosis as well as defining better treatment strategies in relieving GERD and GERD complications.

研究概览

详细说明

Gastroesophageal reflux disease (GERD) and its troublesome complications constitute serious diagnostic and management challenges to the development of safe feeding and airway protection strategies among infants convalescing in the neonatal intensive care units; thus contributing to prolonged lengths of stay, recurrent hospitalizations, and death. GERD is frequently diagnosed by inadequate criteria, and the relative risks, benefits and indications of GERD therapies are unclear. Significant gaps in knowledge exist in understanding the complex causal or adaptive aerodigestive protective reflex mechanisms implicated in GERD in infants. The long-term goal is to improve digestive health, nutrition, and infant development through the design of simplified personalized treatment paradigms by better understanding the pathophysiology of aerodigestive reflexes.

The current objective is to conduct a prospective single center randomized blinded controlled trial comparing the short term effects of the investigators innovative feeding strategy bundle (study approach) versus standard feeding approach (conventional approach).

研究类型

介入性

注册 (实际的)

76

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Ohio
      • Columbus、Ohio、美国、43205
        • The Research Institute at Nationwide Children's Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

7个月 至 1年 (孩子)

接受健康志愿者

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Hospitalized infants with aerodigestive or GERD symptoms
  • Gestational age ≤42 weeks
  • Premature infants are eligible at 34 weeks postmenstrual age (PMA)
  • Enteral or Oral Fed
  • Average daily total feeding volume ≥ 150ml/kg/day
  • Room air or supplemental oxygen of ≤1 liter/minute (LPM) and/or ≤ 35% by nasal cannula

Exclusion Criteria:

  • Known genetic, metabolic or syndromic disease
  • Neurological diseases such as Grade 3 or 4 intraventricular hemorrhage (IVH) or intracranial hemorrhage (ICH) and perinatal asphyxia
  • Gastrointestinal malformations and surgical gastrointestinal conditions

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:Study
Treated with omeprazole. This group of subjects will have prescribed restricted feeding volumes, monitored feeding duration time and positioning restrictions
  • Omeprazole 0.5-1.5 milligrams/kilogram/dose twice a day (BID)
  • Total fluid volume restriction (120-140 milliliters/kilogram/day)
  • Feeding duration over 30 minutes
  • Infant feeds with right side down
  • Infant is placed on back following feeds
其他:Conventional
Treated with omeprazole. This group of subjects will receive the current standard treatment for Gastro-esophageal reflux disease (GERD) which includes use of acid suppressive medication with no restrictions of the feeding volume, duration or positioning.
-Omeprazole 0.5-1.5 milligrams/kilogram/dose twice a day (BID)

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
CLINICAL OUTCOME OF FEEDING SUCCESS
大体时间:Up to 5 weeks after enrollment
The primary endpoint is the feeding success defined as achieving full oral feeds (defined as no need for tube feeds to maintain hydration and nutrition) and/or a >/= 6 point decrease from baseline symptom score as described by the Infant-Gastro-Esophageal Reflux Questionnaire-Revised. The minimum score is 0 (no symptoms) and the maximum score is 42 (maximum symptoms). Any total score greater than or equal to 16 is considered abnormal.
Up to 5 weeks after enrollment
MOTILITY OUTCOMES: Presence of Esophageal Peristaltic Reflexes
大体时间:5 weeks
This is part of Aim 2 of this RCT, which is a mechanistic outcome designed to understand the reasons for the clinical outcome. Presence of peristaltic reflex mechanisms elicited upon esophageal provocation during esophageal manometry were compared within the groups, week-5 vs. week-0. Odds ratios (ORs) with 95% confidence interval (CI) are reported from Generalized Estimation Equation models.
5 weeks

次要结果测量

结果测量
措施说明
大体时间
CLINICAL OUTCOMES: Growth Outcome Measure
大体时间:at 5 weeks
Growth: The investigators will measure and track weight growth velocity during the study period
at 5 weeks
CLINICAL OUTCOME: Development Outcome Measures
大体时间:Up to 1 year age
Feeding Milestones: The investigators will track feeding method at 1 year.
Up to 1 year age
CLINICAL OUTCOME: Respiratory Outcome Measures
大体时间:at discharge
Supplemental oxygen requirement at discharge was recorded for both groups
at discharge

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Sudarshan R Jadcherla, MD、The Research Institute at Nationwide Children's Hospital

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2012年12月1日

初级完成 (实际的)

2020年3月31日

研究完成 (实际的)

2020年3月31日

研究注册日期

首次提交

2015年6月17日

首先提交符合 QC 标准的

2015年6月26日

首次发布 (估计)

2015年7月1日

研究记录更新

最后更新发布 (实际的)

2020年7月29日

上次提交的符合 QC 标准的更新

2020年7月24日

最后验证

2020年7月1日

更多信息

与本研究相关的术语

其他研究编号

  • 11-00734
  • R01DK068158 (美国 NIH 拨款/合同)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅